Up‐regulation of plakophilin‐2 is correlated with the progression of glioma

Glioma is the most common type of primary brain tumor in the CNS. Due to its poor prognosis and high mortality rates, it is urgent to find out more effective therapies. Plakophilin‐2 (PKP2) is a widespread desmosomal plaque protein. Recently, the important roles of PKP2 in the proliferation and migr...

Full description

Saved in:
Bibliographic Details
Published in:Neuropathology 2017-06, Vol.37 (3), p.207-216
Main Authors: Zhang, Degeng, Qian, Yuxia, Liu, Xiaoxing, Yu, Hong, Zhao, Niangao, Wu, Zhengdong
Format: Article
Language:English
Subjects:
Adult
Brain cancer
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Brain tumors
Cell Line, Tumor
Cell Movement
Cell Proliferation
Central nervous system
Cholecystokinin
Disease Progression
Down-Regulation
Female
Glioma
Glioma - genetics
Glioma - pathology
Glioma cells
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Ki-67 Antigen - metabolism
Male
Middle Aged
migration
Neoplasm Grading
PKP2
Plakophilins - genetics
Prognosis
proliferation
Up-Regulation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioma is the most common type of primary brain tumor in the CNS. Due to its poor prognosis and high mortality rates, it is urgent to find out more effective therapies. Plakophilin‐2 (PKP2) is a widespread desmosomal plaque protein. Recently, the important roles of PKP2 in the proliferation and migration of cancer cells and tumor progression has been shown. However, the expression and potential function of PKP2 in glioma was still unclear. In this study, we demonstrated that PKP2 protein expression level was increased in glioma tissues compared with normal brain tissues, and its level was significantly associated with the Ki‐67 expression and WHO grade by Western blot analysis and immunohistochemistry. Clinically, high PKP2 expression was tightly related to poor prognosis of glioma patients. Interestingly, we found that down‐regulated PKP2 expression was shown to inhibit the migration of cells in glioma. Moreover, cell counting kit (CCK)‐8 and colony formation analyses proved that reduced expression of PKP2 could weaken glioma cell proliferation. Taken together, these data uncover a potential role for PKP2 in the pathogenic process of glioma, suggesting that PKP2 may be a promising therapeutic target of glioma.
ISSN:0919-6544
1440-1789
DOI:10.1111/neup.12363